Isoforms of the orphan nuclear receptor COUP‑TFII differentially modulate pancreatic cancer progression

Int J Oncol. 2022 May;60(5):55. doi: 10.3892/ijo.2022.5345. Epub 2022 Mar 29.

Abstract

The expression of the nuclear receptor transcription factor (TF) COUP‑TFII is broadly associated with cell differentiation and cancer development, including of pancreatic ductal adenocarcinoma (PDAC), a devastating disease with one of the poorest prognoses among cancers worldwide. Recent studies have started to investigate the pathological and physiological roles of a novel COUP‑TFII isoform (COUP‑TFII_V2) that lacks the DNA‑binding domain. As the role of the canonical COUP‑TFII in PDAC was previously demonstrated, the present study evaluated whether COUP‑TFII_V2 may have a functional role in PDAC. It was demonstrated that COUP‑TFII_V2 naturally occurs in PDAC cells and in primary samples, where its expression is consistent with shorter overall survival and peripheral invasion. Of note, COUP‑TFII_V2, exhibiting nuclear and cytosolic expression, is linked to epithelial to mesenchymal transition (EMT) and cancer progression, as confirmed by nude mouse experiments. The present results demonstrated that COUP‑TFII_V2 distinctively regulates the EMT of PDAC and, similarly to its sibling, it is associated with tumor aggressiveness. The two isoforms have both overlapping and exclusive functions that cooperate with cancer growth and dissemination. By studying how PDAC cells switch from one isoform to the other, novel insight into cancer biology was gained, indicating that this receptor may serve as a novel possible target for PDAC management.

Keywords: COUP‑TFII; cancer; epithelial to mesenchymal transition; nuclear receptor; stem cell.

MeSH terms

  • Animals
  • COUP Transcription Factor II / genetics*
  • Carcinoma, Pancreatic Ductal* / genetics
  • Epithelial-Mesenchymal Transition
  • Humans
  • Mice
  • Orphan Nuclear Receptors
  • Pancreatic Neoplasms* / genetics
  • Protein Isoforms / genetics

Substances

  • COUP Transcription Factor II
  • Orphan Nuclear Receptors
  • Protein Isoforms

Grants and funding

This work was supported by Fondo per gli Investimenti della Ricerca di Base (grant no. RBAP 10MY35_002), by Fondazione CR di Firenze (grant no. 2013.0673) and by FiorGen ONLUS to AG. AG is an Investigator Grant recipient of the 'AIRC Foundation for Cancer Research' (grant no. IG 2017-20590).